Hepion pharmaceuticals presents machine learning “learn and confirm” modeling strategy at 4th global nash congress

Edison, n.j., april 29, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa, “hepion”), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and liver disease, announced that its senior vice-president, clinical pharmacology and analytics, dr. patrick mayo, gave a virtual presentation entitled “crv431 – from benchtop to bedside clinical development” today at the 4th global nash congress.
HEPA Ratings Summary
HEPA Quant Ranking